5
#000000
#FFFFFF
big pharma
Defending TrumpRx Scam, RFK Jr. Absurdly Claims Trump 'Has His Own Way of Calculating' Percentages
"You can't just redefine how you calculate percentages," said one mathematician in response to Kennedy's claims.
Apr 22, 2026
US Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday tried to defend President Donald Trump's mathematically absurd claims about prescription drug prices by saying the president has his own unique method of calculating percentages.
During a Senate Finance Committee hearing, Sen. Elizabeth Warren (D-Mass.) grilled Kennedy about the president's repeated false claims that he has slashed the prices of prescription drugs by as much as 600%, which would mean that pharmaceutical companies are paying consumers to take their medications.
"President Trump has his own way of calculating," Kennedy replied. "There's two ways of calculating percentages. If you have a $600 drug, and you reduce it to $10, that's a 600% reduction."
RFK Jr: "President Trump has a different way of calculating percentages. If you have a $600 drug and you reduce it to $10, that's a 600% reduction." pic.twitter.com/MjDNADqc8p
— Aaron Rupar (@atrupar) April 22, 2026
In fact, such a drop in price would represent a 98.3% reduction, less than one-sixth the size of the president's claims. A 600% reduction in the price of a $600 drug would mean that drug manufacturer paid consumers $3,000 every time they picked up their prescription.
Kit Yates, a mathematician at the University of Bath, marveled at Kennedy's attempts to create an alternate version of arithmetic.
"We've known for a while that the USA's current regime have been out for science, but I never thought they would try to mess with math!" Yates wrote in a social media post. "You can't just redefine how you calculate percentages."
In addition to exposing Kennedy's apparent ignorance of elementary mathematics, Warren shined a light on how the TrumpRx website misleads consumers into thinking they're being offered bargains on prescription drugs that are available elsewhere in generic varieties.
In once instance, Warren noted that TrumpRx is selling a brand-name heartburn medication for $200, whereas a generic version of the same drug is available at Costco for $16. Warren also highlighted a heart arrhythmia drug for sale on TrumpRx for $336, even though a generic version of the drug is available at Costco for $12.
Warren added that, in exchange for making select brand-name drugs available on the TrumpRx website, pharmaceutical companies have gotten exemptions from the president's 100% tariffs on imported patented medicines.
"Think about that: Big Pharma makes billions of dollars in tariff relief by listing their drugs on TrumpRx, and then they don't even lower the costs on many of these drugs," she said. "That is a great deal for Big Pharma."
Warren's analysis of TrumpRx's pricing scheme echoes a March report from the Center for American Progress (CAP), which found that the president's prescription drug website offered genuinely lower prices on “exactly one” of the 54 medications listed.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Reuters reported in December that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
Later in the Senate Finance Committee hearing, Sen. Bernie Sanders (I-Vt.) ridiculed Kennedy for claiming that, under Trump's leadership, "the American people are now paying the lowest costs in the world rather than the highest for prescription drugs."
"That is an absurd statement," Sanders said. "Nobody in the world believes that."
Keep Reading
Show Less
Patient Advocates Warn Trump Pharma Tariffs Could 'Drive Up Costs and Create More Uncertainty'
One campaigner urged the administration to "focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Apr 02, 2026
On Thursday, the one-year anniversary of President Donald Trump's so-called Liberation Day, US advocacy groups sounded the alarm about his new tariffs targeting "patented pharmaceuticals and their ingredients under Section 232 of the Trade Expansion Act of 1962 to bolster American national security and public health."
The administration announced a year ago that the US Department of Commerce would conduct a related investigation under that law. The resulting report was recently sent to the president, and although the findings have not been made public, Trump's executive order summarizes key takeaways and Secretary Howard Lutnick's recommended actions.
According to the order, the secretary's recommendations included "continuing to negotiate onshoring agreements related to most favored nation (MFN) pharmaceutical pricing agreements; imposing significant tariffs on pharmaceuticals and pharmaceutical ingredients, so that such imports will not threaten to impair the national security of the United States; and granting preferential treatment to those companies that commit to onshore production of pharmaceuticals and pharmaceutical ingredients."
Citing an unnamed Trump administration official, The Washington Post reported Thursday that "the White House has reached agreements with 13 drugmakers and expects to soon conclude an additional four." As part of these deals, companies are planning to invest at least $400 billion in new US plants.
The Post also pointed out that "some imported drugs will face much lower tariffs under trade deals Trump negotiated with five US trading partners. Goods from the European Union, Japan, South Korea, and Switzerland will face 15% levies, while drugs from the United Kingdom, which was the first to sign a deal with Trump, will be hit with a 10% tariff."
Thanks to Trump's new order, brand-name pharmaceuticals made in other countries could be hit with tariffs as high as 100%.
Merith Basey, CEO of Patients for Affordable Drugs, warned in a statement that "while these tariffs aim to pressure pharmaceutical corporations into US manufacturing and most favored nation agreements, the current MFN deals remain opaque and voluntary, and have not delivered meaningful savings for the vast majority of American patients. There's a real risk these tariffs will drive up costs and create more uncertainty for millions of patients already struggling to afford their medications."
Experts at Public Citizen, another advocacy group that has sued to expose the secretive MFN agreements, were similarly critical.
"By announcing these tariffs without even producing the evidence from the investigation that supposedly justifies them, Trump is continuing his pattern of grabbing headlines by using the word 'tariff' while engaging in secretive ongoing negotiations and opaque exemptions processes that are ripe for corporate corruption," said Public Citizen Global Trade Watch director Melinda St. Louis—who also wrote a broader takedown of Trump's trade policy published Thursday by Common Dreams.
"While strategic tariffs can be used to support domestic manufacturing and good jobs, they must be paired with real public investments and support for workers' rights, which Trump has systematically undermined," she said. "Instead, he's bullying other countries like the UK into paying more for medicines, which will lead to windfall profits for Big Pharma and do nothing to reduce US prices."
Peter Maybarduk, director of Access to Medicines at Public Citizen, stressed that "Trump's tariffs will be either ineffective or harmful for what people need, which is a reliable, plentiful, affordable supply of medicine."
Also taking aim at the "secretive arrangements that allow Trump to claim specious victories on manufacturing and high drug prices," Maybarduk explained that "in reality, many manufacturing commitments claimed under the deals were part of previously planned projects and the drug pricing commitments appear designed to largely spare drug company profits rather than earnestly address affordability concerns."
"Meanwhile the administration has given drugmakers perks like lucrative vouchers to accelerate FDA review of their medicines and a promise from the Trump administration that it will bully other countries into adopting higher prescription drug prices, using tariffs as leverage," he continued, referring to the Food and Drug administration.
"If the administration wants to fix problems like medicines shortages and fragile supply chains," he argued, "it should focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Keep Reading
Show Less
‘A System Rigged’: Untaxed Wealth of Richest 0.1% Is More Than Assets of World’s Poorest Half
A decade after the Panama Papers, the global rich are still hiding more than $2.8 trillion in tax havens. Just a fraction of that money could end extreme hunger and provide clean water to everyone on Earth.
Apr 02, 2026
The richest 0.1% of people on Earth are hiding more than $2.8 trillion in offshore accounts to avoid taxes. That money alone is more wealth than is owned by the entire bottom half of humanity, more than 4.1 billion people.
These findings were published in a report released Thursday by Oxfam International on the 10th anniversary of the 2016 Panama Papers, which provided an unprecedented look at how the world's most powerful capitalists, financiers, political leaders, celebrities, and criminals exploited offshore tax havens to stash their money.
"Ten years on, the superrich are still sequestering oceans of wealth in offshore vaults,” said Christian Hallum, Oxfam International’s tax lead.
The percentage of untaxed wealth in offshore accounts has dropped in the past 10 years, in large part due to global reforms like the adoption of the Organization for Economic Cooperation and Development's Automatic Exchange of Information framework (AEOI), which allows revenue authorities around the world to easily share information and crack down on cheats.
However, many nations in the Global South are excluded from this system, even though they need the tax revenue the most.
Oxfam found that a staggering $3.5 trillion, more than 3.2% of the global gross domestic product, still remains in untaxed accounts. That's more than the entire GDP of France and is more than twice the combined wealth of the world's 44 poorest nations.
And while the percentage of untaxed wealth is shrinking, that doesn't mean inequality has shrunk.
On the contrary, the December 2025 "World Inequality Report" found that the richest 0.001% of humanity—fewer than 60,000 multimillionaires and billionaires—now have three times as much wealth as the poorest half of the world’s population combined.
Inequality has surged around the world in part due to taxation policies and pandemic recovery packages that overwhelmingly favor the rich. The most glaring was adopted in the world's financial hub, the United States, last year.
The megabudget passed by Republicans and signed into law by President Donald Trump handed a $1 trillion tax cut to America's wealthiest 1% while slashing more than $1 trillion in spending from Medicaid, food assistance, and other safety net programs. It has been described by some economists as the largest upward transfer of wealth in US history.
While the global top 0.1% holds about 80% of untaxed offshore wealth, an even smaller group of uber-wealthy individuals does most of the cheating. The world's richest 0.01%, who hold at least $50 million apiece, control about half of all money in global tax shelters—$1.7 trillion.
According to the Tax Justice Network's Corporate Tax Haven Index, Caribbean islands under UK ownership, including the British Virgin Islands, the Cayman Islands, and Bermuda, are among the worst offenders. Other notable tax havens include Switzerland, Singapore, Hong Kong, Ireland, and the Netherlands.
A February Oxfam report on Elon Musk, who is well on his way to becoming the world's first trillionaire, found that his company, Tesla—which managed to pay zero dollars on its $2.3 billion income in 2024—has not published a country-by-country report on its taxes and that it has subsidiaries in many countries considered to be tax havens.
Big Pharma companies, including AbbVie and Merck, also used tax shelters to lower their total tax expense in 2025 by more than $1 billion, according to a report released earlier this month by the Financial Accountability & Corporate Transparency Coalition.
"This isn’t just about clever accounting—it’s about power and impunity," Hallum said. "When millionaires and billionaires stash trillions of dollars in offshore tax havens, they place themselves above the obligations that bind the rest of society."
"The consequences are as predictable as they are devastating," he continued. "We see our public hospitals and schools starved of funds, our social fabric shredded by rising inequality, and ordinary people forced to shoulder the costs of a system rigged to enrich a tiny few.”
Even a fraction of the money currently stashed away by the world's wealthiest could alleviate untold amounts of suffering.
In November, the United Nations' World Food Program estimated that extreme hunger, which currently affects more than 318 million people around the world, could be eradicated by 2030 with investments of about $93 billion per year, but that global hunger programs instead remain “slow, fragmented, and underfunded."
According to a 2021 UN Educational, Scientific, and Cultural Organization (UNESCO) report, investments of around $114 billion per year would similarly be enough to ensure that everyone on Earth has access to safe drinking water and sanitation.
Oxfam called on governments around the world to increase coordination to prevent the wealthy from hiding their riches from tax authorities. It also urged them to adopt more aggressive policies to tax the 1%'s wealth at home, including taxes on income and on extreme wealth.
Keep Reading
Show Less
Most Popular